Published : 15 May 2024
Aagami, Inc. are pleased to announce that another US client has awarded a contract extension to support them in JV/Acquisition initiatives. We thank the client and keen to help the client fulfil their needs and objectives.
The client is seeking Acquisition /JV for their extremely safe and effective Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial Ongoing in AU).
The asset has applicability for a host of other indications. Patents are granted in all 12 regions applied.
Aagami are also representing the client at BIO 2024 San Diego (June 3-6).
If you would like to know more about this opportunity, please contact us.